Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
anti-ADAM9-DM4
- Development stage
- Preclinical
- Lead developer
- MacroGenics
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
anti-ADAM9-DM4 is a preclinical antibody-drug conjugate (ADC) developed through a collaboration between ImmunoGen and MacroGenics. It consists of a high-affinity monoclonal antibody targeting ADAM9 (A Disintegrin and Metalloproteinase 9) conjugated to the maytansinoid microtubule disruptor DM4 via a hindered disulfide sulfo-SPDB linker. ADAM9 is a cell surface protease overexpressed in various solid tumors, including lung, pancreatic, renal, and prostate cancers, where its expression correlates with poor prognosis. In preclinical studies, anti-ADAM9-DM4 demonstrated potent in vitro cytotoxicity across multiple ADAM9-positive tumor cell lines and induced significant tumor growth delay in xenograft models of non-small cell lung cancer (NSCLC).
- Other names
- ADAM9-DM4 ADCADAM-9-DM4 ADCADAM 9-DM4 ADC
02
Targets
TUBB (Tubulin (alpha and beta subunits))ADAM9
Beyond the preview
Go deeper on anti-ADAM9-DM4.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on anti-ADAM9-DM4.